Tags

Type your tag names separated by a space and hit enter

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
PLoS One. 2020; 15(5):e0233693.Plos

Abstract

Efavirenz-based first-line regimens have been widely used for children ≥3 years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6-18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11).

Authors+Show Affiliations

Center for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.Center for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.Empilweni Services and Research Unit, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa.Kheth'Impilo AIDS Free Living, Cape Town, Western Cape, South Africa. Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, Cape Town, Western Cape, South Africa.University of Stellenbosch, Stellenbosch, Cape Town, Western Cape, South Africa. Tygerberg Academic Hospital, Cape Town, Western Cape, South Africa.Africa Health Research Institute, KwaZulu-Natal, Durban, South Africa. Lincoln International Institute for Rural Health, University of Lincoln, Lincoln, England, United Kingdom. School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.Center for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa. Khayelitsha ART Program, Cape Town, Western Cape, South Africa. Western Cape Department of Health, Cape Town, Western Cape, South Africa.Center for Infectious Diseases Epidemiology and Research, School of Public Health an Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa. Gugulethu ART Program, Cape Town, Western Cape, South Africa.Red Cross War Memorial Children's Hospital, Cape Town, Western Cape, South Africa. Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, South Africa.Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.McCord Hospital, Durban, South Africa.Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, University of Witwatersrand, Johannesburg, South Africa.Gertrude H Sergievsky Center, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America.Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

32469985

Citation

Nyakato, Patience, et al. "Virologic Response to Efavirenz-based First-line Antiretroviral Therapy in Children With Previous Exposure to Antiretrovirals to Prevent Mother-to-child Transmission." PloS One, vol. 15, no. 5, 2020, pp. e0233693.
Nyakato P, Davies MA, Technau KG, et al. Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE. 2020;15(5):e0233693.
Nyakato, P., Davies, M. A., Technau, K. G., Fatti, G., Rabie, H., Tanser, F., Boulle, A., Wood, R., Eley, B., Sawry, S., Giddy, J., Sipambo, N., Kuhn, L., & Fairlie, L. (2020). Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PloS One, 15(5), e0233693. https://doi.org/10.1371/journal.pone.0233693
Nyakato P, et al. Virologic Response to Efavirenz-based First-line Antiretroviral Therapy in Children With Previous Exposure to Antiretrovirals to Prevent Mother-to-child Transmission. PLoS ONE. 2020;15(5):e0233693. PubMed PMID: 32469985.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. AU - Nyakato,Patience, AU - Davies,Mary-Ann, AU - Technau,Karl-Gunter, AU - Fatti,Geoffrey, AU - Rabie,Helena, AU - Tanser,Frank, AU - Boulle,Andrew, AU - Wood,Robin, AU - Eley,Brian, AU - Sawry,Shobna, AU - Giddy,Janet, AU - Sipambo,Nosisa, AU - Kuhn,Louise, AU - Fairlie,Lee, AU - ,, Y1 - 2020/05/29/ PY - 2019/09/02/received PY - 2020/05/11/accepted PY - 2020/5/30/entrez PY - 2020/5/30/pubmed PY - 2020/5/30/medline SP - e0233693 EP - e0233693 JF - PloS one JO - PLoS ONE VL - 15 IS - 5 N2 - Efavirenz-based first-line regimens have been widely used for children ≥3 years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6-18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11). SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/32469985/Virologic_response_to_efavirenz-based_first-line_antiretroviral_therapy_in_children_with_previous_exposure_to_antiretrovirals_to_prevent_mother-to-child_transmission L2 - https://dx.plos.org/10.1371/journal.pone.0233693 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.